Provides cloud software that analyzes genomic and other health data for healthcare providers, research laboratories and biopharmaceutical companies.
20-F for FY2025, filed Mar 3, 2026
Healthcare customers are charged for each platform analysis when results are made available; DNA kits are charged on delivery, and Alamut software access is spread over the agreement. Biopharma work is generally charged when a final report is issued or trial participants are recruited.
20-F for FY2025, filed Mar 3, 2026The majority of the SOPHiA DDM Platform revenue is derived from each use of the SOPHiA DDM Platform by customers to generate analyses on…View ↗
F-14 upload their patient data to the SOPHiA DDM Platform for analysis. In these arrangements, the Company has identified two performance…View ↗
The Company also sells access to its Alamut software application (“Alamut”) through the SOPHiA DDM Platform. Some arrangements with…View ↗
Generally, the primary performance obligation in these arrangements is the delivery of analysis results in the form of a final report…View ↗
$77.3M
20-F for FY2025, filed Mar 3, 2026
$77.3M ↗
Healthcare providers, research laboratories and biopharmaceutical companies use its platform. The company sells directly and through distributors, and works with other healthcare providers to assemble solutions for customers.
20-F for FY2025, filed Mar 3, 2026
No. It lost $79M in FY2025.
Growing. Revenue grew 91% in 4 years, from $40.5M in FY2021 to $77.3M in FY2025, about 18% a year.
Radiomics added to CarePath
The older report described CarePath as a multimodal module and said radiomics would be integrated later; the latest report says CarePath incorporates the radiomics offering and is deployed in its Digital Twins research tool.
20-F for FY2022, filed Mar 7, 2023 20-F for FY2025, filed Mar 3, 2026In 2014, we launched the first application of our platform to analyze NGS data for cancer diagnosis. We offer a broad range of applications…View ↗
In 2014, we launched the first application of our platform to analyze NGS data for cancer diagnosis. We offer a broad range of applications…View ↗
Competes with Tempus Labs, F. Hoffmann-La Roche, Caris Life Sciences, Siemens, Koninklijke Philips, Konika Minolta, Agilent, Fabric Genomics, Illumina, Qiagen Digital Insights, Velsera, Congenica, and Thermo Fisher
20-F for FY2025, filed Mar 3, 2026We operate in a market characterized by rapidly advancing technologies and a strong emphasis on intellectual property. Our main competitors…View ↗
Loading...